About Us - Company Profile

Glenmark Generics Limited aims to be a global integrated Generic and API leader. The Company currently markets finished dose formulations in USA, Europe, and Argentina and has Active Pharmaceutical Ingredients (APIs) presence in over 80 countries through an established group of subsidiaries, marketing front-ends and offices in India and select overseas locations.

GGL has a strong base in Formulation development with teams operating out of laboratories in India and Argentina. The Company has a state-of-the-art manufacturing plant at Goa, India that has been inspected by US FDA, TPD (Canada), MHRA, UK and many other overseas regulatory authorities. GGL also markets over 45 APIs to more than 80 countries across the world and had over 35 USDMFs filed and/or approved along with several DMFs in Canada and Europe.

Glenmark’s API division possesses strong, dedicated process research capabilities and a dedicated team of scientists equipped with the best analytical tools and a sophisticated information centre. Currently, GGL has three API manufacturing plants in India of which its plant at Ankhleshwar has been inspected by USFDA and several other international regulatory bodies.

Snapshot 

  • The Generics business has been built over the last 5 years
  • Comprising of US & EU generics, API and Argentina Oncology SBUs
  • GGL focuses on developing, manufacturing, selling, and the distribution of generics through wholesalers, retailers and pharmacy chains etc
  • End to End vertically integrated into the generic market (From API to front end marketing capabilities)
  • Focused on certain key niche market segments including: Dermatology, Hormones, Controlled Substances, Oncology, and Modified Release
  • GGL is a subsidiary of Glenmark Pharmaceuticals Ltd.

 

GGL's US subsidiary Glenmark Generics Inc (erstwhile Glenmark Pharmaceuticals Inc.) that was incorporated in 2004 - posted revenue of USD 157.9 Mn for FY 08-09 against revenue of USD 140.03 Mn registering an increase of 30 % over the previous year. GGI has grown the generic base in the US at a healthy CAGR of 130 % over the last 3 years. 

  • Presence in controlled substances, hormones, oncology, modified release and dermatology
  • GGL received its first 180 day (shared) exclusivity for marketing Oxcarbazepine (Generic of Trileptal®)
  • Filed PIVs (FTF opportunities) for Zetia®, Tarka®, Cutivate® & Malarone®
  • Over 45 products currently sold in the market
  • About 50 products filed with USFDA for approval
  • Portfolio of marketed products has doubled each year during the last three years
  • Glenmark Generics Inc has entered into strategic partnerships for controlled substances, development of dermatology products and for oral solids

 

GGL's EU subsidiary Glenmark Generics (Europe) Ltd. (erstwhile Glenmark Pharmaceuticals (Europe)) was established in 2004.
  •  FY 0809 saw GGEL's first product launch, Perindopril, in 3 western european markets
  • Product portfolio comprises of 4 approved MAs, 10 applications currently going thought registration procedures across Europe
  • Portfolio of more than 35 EU CTD solid and semi-solids dossiers at various stages of development
  • Several supply deals are in place with leading European generic players
  • It entered into a strategic product development agreement with Mylan (Merck Generics) for three dermatology products
  • Supply deals have been executed with five leading EU generic players

Glenmark acquired the Argentinean company Servycal S.A. with a focused oncology portfolio.

  • Presence in oncology in over 20 countries

  • Caters to about 75% of cancer therapy products

  • Presence in cytotoxics, anti-hormonals and supportive therapies

In the API domain, GGL has:

  • Presence across 80 countries including regulated markets like US and Europe

  • Over 35 USDMFs filed along with several DMFs in Canada

  • Filed over 100 process patents in the last 3 year

  • Several supplies to regulated market customers for first to file ANDA’s

  • Market leader in the Less regulated markets on several products including Telmisartan, Diacerin, Olmesartan and Linezolid. Market leader in South America for Bupropion

  • Direct presence of sales teams in key markets of US, UK, Brazil and India


© 2008 Glenmark Generics Ltd.